{
    "nctId": "NCT05585034",
    "briefTitle": "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb\u00ae808 in Combination With Pembrolizumab in Advanced Solid Tumors",
    "officialTitle": "A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb\u00ae808 in Combination With Pembrolizumab in Selected Advanced Solid Tumors",
    "overallStatus": "RECRUITING",
    "conditions": "Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 220,
    "primaryOutcomeMeasure": "Incidence of treatment-emergent adverse events (TEAEs)",
    "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Part A: Histologically confirmed advanced/metastatic castration-resistant prostate adenocarcinoma, epithelial ovarian cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, urothelial carcinoma, melanoma, renal cell carcinoma, triple-negative breast cancer, or colorectal cancer that has progressed on standard therapies\n* Part B: Histologically confirmed advanced/metastatic castration-resistant prostate cancer that is PD1-na\u00efve; head and neck squamous cell carcinoma that is PD1-na\u00efve or has progressed on prior PD1 therapy; or melanoma that is PD1-na\u00efve or has progressed on prior PD1 therapy\n* Measurable disease by RECIST 1.1; subjects with prostate cancer who have evaluable disease according to PCWG3 criteria may enroll\n* Life expectancy \\> 3 months\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nKey Exclusion Criteria:\n\n* Subjects currently receiving other anticancer therapies\n* Any prior treatment with an investigational agent targeting CD28\n* History of a life-threatening adverse event related to prior immunotherapy\n* Known active central nervous system involvement by malignant disease. Subjects with previously treated brain metastases may participate provided they are radiologically and clinically stable",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}